OTCMKTS:CLPBY Coloplast A/S (CLPBY) Stock Price, News & Analysis $6.18 0.00 (0.00%) As of 10/2/2026 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsInsider TradesNews and TrendsShort Interest About Coloplast A/S Stock (OTCMKTS:CLPBY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Coloplast A/S alerts:Sign Up Key Stats Today's Range$6.16▼$6.2950-Day Range$6.18▼$7.4052-Week Range$5.64▼$9.70Volume667,826 shsAverage Volume225,138 shsMarket Capitalization$13.93 billionP/E Ratio32.53Dividend Yield1.29%Price TargetN/AConsensus RatingHold Company Overview Coloplast A/S is a Denmark-based medical technology company that develops and markets products and services for people with intimate and chronic healthcare needs. Its principal business areas include ostomy care, continence care, wound and skin care, and interventional urology. The company’s product portfolio includes ostomy bags and accessories, skin-protection products, intermittent catheters, bowel-management systems, and devices used in urological procedures. Recognized brands include SenSura and Brava in ostomy care, SpeediCath in continence care, and Peristeen for bowel management. Coloplast traces its origins to the 1950s, when nurse Elise Sørensen developed an adhesive ostomy bag to help her sister manage an ileostomy. The company was established in 1957 by Aage Louis-Hansen and his wife, Johanne Louis-Hansen. Headquartered in Humlebæk, Denmark, Coloplast serves healthcare professionals and patients in markets across Europe, North America, and other international regions. Kristian Villumsen has served as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Coloplast A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreCLPBY MarketRank™: Coloplast A/S scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingColoplast A/S has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageColoplast A/S has received no research coverage in the past 90 days.Read more about Coloplast A/S's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth2.50% Earnings GrowthEarnings for Coloplast A/S are expected to grow by 2.50% in the coming year, from $0.40 to $0.41 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coloplast A/S is 32.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.66.Price to Earnings Ratio vs. SectorThe P/E ratio of Coloplast A/S is 32.53, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.00.Price to Earnings Growth RatioColoplast A/S has a PEG Ratio of 2.20. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioColoplast A/S has a P/B Ratio of 5.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Coloplast A/S's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Coloplast A/S has been sold short.Short Interest Ratio / Days to CoverColoplast A/S has a short interest ratio ("days to cover") of 0.41, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Coloplast A/S has recently increased by 14.20%, indicating that investor sentiment is decreasing significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldColoplast A/S pays a meaningful dividend of 1.33%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthColoplast A/S does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Coloplast A/S is 42.11%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Coloplast A/S will have a dividend payout ratio of 19.51% next year. This indicates that Coloplast A/S will be able to sustain or increase its dividend.Read more about Coloplast A/S's dividend. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Coloplast A/S this week, compared to 0 articles on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Coloplast A/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsColoplast A/S has minimal institutional ownership at this time.Read more about Coloplast A/S's insider trading history. Receive CLPBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coloplast A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLPBY Stock News HeadlinesHead to Head Analysis: Elutia (NASDAQ:ELUT) and Coloplast A/S (OTCMKTS:CLPBY)3 hours ago | americanbankingnews.comHead to Head Contrast: Coloplast A/S (OTCMKTS:CLPBY) and Nuwellis (NASDAQ:NUWE)September 28, 2026 | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 5 at 1:00 AM | Profits Run (Ad)Critical Contrast: Beyond Air (NASDAQ:XAIR) and Coloplast A/S (OTCMKTS:CLPBY)September 24, 2026 | americanbankingnews.comCLPBY Share News TodayJune 22, 2026 | uk.investing.comColoplast's Next Generation Inflatable Penile Prosthesis Approved by the FDA – can help millions of menJune 3, 2026 | globenewswire.comColoplast: Went 'BUY' A Bit EarlyMay 16, 2026 | seekingalpha.comColoplast: The Market Is Throwing Away A High-Quality CompounderMarch 17, 2026 | seekingalpha.comSee More Headlines CLPBY Stock Analysis - Frequently Asked Questions How have CLPBY shares performed this year? Coloplast A/S's stock was trading at $8.50 on January 1st, 2026. Since then, CLPBY shares have decreased by 27.3% and is now trading at $6.18. How were Coloplast A/S's earnings last quarter? Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) released its quarterly earnings data on Tuesday, August, 18th. The company reported $0.10 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.10. The business had revenue of $1.14 billion for the quarter, compared to analysts' expectations of $1.11 billion. Coloplast A/S had a trailing twelve-month return on equity of 39.27% and a net margin of 9.68%. How do I buy shares of Coloplast A/S? Shares of CLPBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/18/2026Today10/05/2026Next Earnings (Estimated)11/03/2026Fiscal Year End9/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolOTCMKTS:CLPBY Previous SymbolNASDAQ:CLPBY CIK1294325 Webwww.coloplast.com Phone(454) 911-1111FaxN/AEmployees17,156Year Founded1957Profitability EPS (Trailing Twelve Months)$0.19 Trailing P/E Ratio32.53 Forward P/E Ratio15.45 P/E Growth2.2Net Income$538.49 million Net Margins9.68% Pretax Margin13.97% Return on Equity39.27% Return on Assets11.54% Debt Debt-to-Equity Ratio1.51 Current Ratio1.56 Quick Ratio0.94 Sales & Book Value Annual Sales$4.13 billion Price / Sales3.37 Cash Flow$0.36 per share Price / Cash Flow17.23 Book Value$1.06 per share Price / Book5.83Miscellaneous Outstanding Shares2,253,670,000Free FloatN/AMarket Cap$13.93 billion OptionableNot Optionable Beta0.21 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:CLPBY) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coloplast A/S Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Coloplast A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
